media – Page 239 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Maghreb Pharma Expo

Organiser: Easy Fairs Time: April 21 – 23, 2025 Address: Palais des expositions Pins Maritimes, Algiers 16000, Algeria Exhibition hall: Safex Expo Center Product range: Medical Products Zone: Medical diagnostic equipment & supplies, electronic medical devices & instruments, ambulance equipment, medical reagents & devices, etc. Hospital Supplies Zone: Catheters, interventional materials, surgical hygiene products, disposable medical consumables, surgical tools, medical clothing & bedding, emergency equipment, maternal & infant care equipment, disinfection equipment, etc. Laboratory Equipment Zone: Laboratory instruments & equipment, optical instruments & equipment, image analysis & processing systems, testing instruments & devices, laboratory renovation & upgradation technologies, consumables, and related software, etc. Pharmaceuticals Zone: Various novel drugs, traditional Chinese medicines, western medicines, traditional medicines, herbal medicines, Chinese medicinal health products, nutritional foods, etc. Pharmaceutical Machinery Zone: Pharmaceutical production equipment & technology, pharmaceutical packaging machinery, pharmaceutical packaging materials, production, cleaning, disinfection, and configuration systems for pharmaceuticals. About Maghreb Pharma Expo： The Maghreb ...
- Source: drugdu
- 438
- September 3, 2024
Down payment of 150 million! Non small cell lung cancer pipeline BD+1

On August 30, 2024, Shanghai Iris Pharmaceutical Technology Co., Ltd. (Iris) (688578. SH) signed a strategic cooperation agreement with Carcos Pharmaceutical (1167. HK). Iris obtained the exclusive license to research, develop, produce, register and commercialize the KRAS G12C inhibitor Golarese and SHP2 inhibitor JAB-3312 in China (including Chinese Mainland, Hong Kong, Macao and Taiwan). According to the terms of the agreement, Elys will pay 150 million yuan in head of state payments, up to 700 million yuan in development and sales milestone payments, and double-digit sales commissions to Gakos for this authorization, including value-added tax. Established in 2004, Elise is an innovative pharmaceutical company dedicated to providing unmet clinical needs for patients worldwide. It was listed on the Shanghai Stock Exchange’s Science and Technology Innovation Board in 2020. Since its establishment, the company has adhered to independent innovation and established a complete new drug research and development system, covering various ...
- Source: drugdu
- 419
- September 3, 2024
Originating from Tsinghua University, a brain computer interface company in China plans to IPO

On August 28th, the official website of the China Securities Regulatory Commission disclosed that Beijing Pinchi Medical Equipment Co., Ltd. (hereinafter referred to as “Pinchi Medical”) has completed the registration of coaching and filing with the Beijing Securities Regulatory Bureau, and plans to conduct an initial public offering and listing. The coaching securities firm is China International Capital Corporation (CICC). It is reported that Pinchi Medical is a leader in the field of neural regulation in China, specializing in the research and development, production, and sales of a series of neural regulation products such as brain pacemakers, vagus nerve stimulators, spinal cord stimulators, and sacral nerve stimulators. 1st developer in China to offer a full range of neural regulation products Since its establishment in 2008, Pinchi Medical has continued to deeply cultivate the field of neural regulation. With profound technological accumulation and innovative spirit, it has undertaken multiple national key ...
- Source: drugdu
- 532
- September 3, 2024
2024 Chinese Small Molecule Targeted Anti Tumor Drugs White Paper

The current development status of the global and Chinese small molecule anti-tumor targeted drug industry China is a major cancer country in the world. The main types of malignant cancer in China are lung cancer, gastric cancer, colorectal cancer, liver cancer, breast cancer and esophageal cancer. The high incidence and death of cancer patients has created a huge demand for innovative therapeutic drugs and treatment schemes. From the perspective of the overall Chinese market, the market size of small molecule anti-tumor drugs in China will reach 73.4 billion yuan in 2023, and it is expected to further grow to 207.5 billion yuan in 2030. The compound annual growth rate during this period is 16.0%, far exceeding the global level during the same period, demonstrating the strong growth momentum of the Chinese market. Representative enterprise of China’s small molecule anti-tumor targeted drug industry – Zhejiang Tongtongkang Pharmaceutical From the perspective of ...
- Source: drugdu
- 299
- September 3, 2024
Warner Pharmaceutical’s Half Year Report Achieves New High in Total Assets, Highly Recommended by Securities Firms

Source: Securities Times · E Company Latest price: 38.25 Price fluctuation: -0.75 Price range: -1.92% Transaction volume: 4481 lots Transaction amount: 17.06 million Turnover rate: 0.48% Price to earnings ratio: 15.9 Total market value: 3.59 billion On August 31st, Warner Bros. Pharmaceutical (688799. SH) released its 2024 semi annual report, achieving a revenue of 739 million yuan in the first half of the year, a year-on-year increase of 2.34%; Realize a net profit attributable to the parent company of 113 million yuan, a year-on-year increase of 0.52%. The basic earnings per share are 1.20 yuan. Simultaneously disclosed is the 2023 annual profit distribution plan, in which the company plans to distribute a cash dividend of 9 yuan (including tax) for every 10 shares to all shareholders, totaling 84.42 million yuan (including tax). If this profit distribution plan is approved by the shareholders’ meeting, the company will distribute a total of ...
- Source: drugdu
- 289
- September 3, 2024
BeiGene’s “BTK Double Swords” Unleashed

When it comes to BeiGene’s BTK, you will think of zanubrutinib without thinking, but BeiGene’s BTK inhibitors are not limited to zanubrutinib. BGB-16673, which is under development in the pipeline, is another potential “sharp sword”. Recently, BeiGene’s BTK PROTAC molecule BGB-16673 was granted fast track qualification by the FDA for CLL/SLL patients who have undergone at least two lines of treatment, including BTK inhibitors and Bcl-2 inhibitors. Since the first BTK inhibitor ibrutinib was approved for marketing in 2013, 6 BTK inhibitors have been approved for marketing worldwide. Although many BTK inhibitors have been approved for marketing and these drugs have demonstrated excellent efficacy, they still have certain limitations, namely the problem of drug resistance. PROTAC (protein degradation) has been a very hot research and development track in recent years. Compared with small molecule inhibitors, PROTAC degraders have many advantages: they expand the druggable targets and can target target proteins ...
- Source: drugdu
- 227
- September 3, 2024
Tumor drugs without OS are also hanging in China

Before this, furiquintinib was regarded as another effective treatment option for gastric cancer patients. After all, gastric cancer is the fifth most common cancer in the world, and my country is a country with a high incidence of gastric cancer, with a large number of patients. With the continuous development of precision medicine, PD-1 combined with chemotherapy has become a new standard for first-line treatment of advanced gastric cancer. However, both in China and around the world, there is still a lack of treatment options available for second-line and above patients. Global pharmaceutical companies have deployed a large number of research in this field to promote clinical trials including PD-1, ADC, and VEGFR inhibitors. Among them, VEGFR inhibitors play a vital role in inhibiting tumor angiogenesis, and studies have shown that gastric cancer tissues often express high levels of VEGF, which is associated with more advanced disease and poor prognosis. ...
- Source: drugdu
- 350
- September 3, 2024
Focusing on complement, standardized diagnosis and treatment of rare diseases usher in a new chapter

So far, the 2024 medical insurance catalog adjustment has announced the drugs and related information that have passed the formal review. From the draft for comments, rare disease drugs are still one of the focuses of the medical insurance catalog adjustment. Rare diseases are also called “orphan diseases”. Most of them are congenital diseases, chronic diseases, and may be life-threatening. Although the incidence of rare diseases is low, there are many types of diseases and the number of patients cannot be underestimated. At present, there are more than 7,000 confirmed rare diseases in the world, and there are about 20 million rare disease patients in China1. For a long time, the clinical phenotypes of rare diseases and common diseases overlap greatly, and early diagnosis is difficult, so the misdiagnosis and missed diagnosis rates are high. According to statistics from the National Organization for Rare Diseases in the United States, among ...
- Source: drugdu
- 236
- September 3, 2024
stable and improving performance in ringgit, the benefits of overseas market development gradually appeared

On August 28, Buchang Pharma (603858) released its 2024 semi-annual report. During the report period, the company realized operating income of 5.432 billion yuan; realized attributable net profit of 231 million yuan; net cash flow from operating activities was 497 million yuan, an increase of 85.62%, the company’s cash reserves are more adequate. In the context of general industry pressure, Buchang Pharma still shows the strong operating resilience of leading enterprises. During the reporting period, the company actively carried out research and development of multiple types of drugs and gradually perfected the big health industry. Since its establishment, Buchang Pharma has become an important force in promoting local economic development. As of July 2024, Buchang Pharma has accumulated more than 30 billion yuan in national tax payments, making significant contributions to the sustainable and sound development of the local economy. According to statistics, since the listing of eight years, Buchang ...
- Source: drugdu
- 166
- September 3, 2024
【EXPERT Q&A】What are the advantages and disadvantages of antibody drugs versus RNA drugs?

Drugdu.com expert’s response: Antibody drugs and RNA drugs are two distinct categories of biotechnology medications, each possessing unique strengths and weaknesses. Below is a detailed analysis of their respective advantages and disadvantages: Ⅰ. Advantages of Antibody Drugs High Specificity: Antibody drugs can specifically recognize and bind to target antigens, typically proteins on cell surfaces, providing a high degree of selectivity that minimizes damage to normal cells. Long-lasting Effect: Antibody drugs typically have longer half-lives, enabling extended duration of action within the body, reducing the frequency of dosing and enhancing patient convenience. Low Immunogenicity: Fully humanized antibody drugs exhibit lower immunogenicity, mitigating the risk of immune reactions and improving drug tolerability and safety. High Success Rate: In clinical studies, antibody drugs demonstrate significantly higher success rates compared to traditional small-molecule chemical drugs. In the US, approximately 25%-30% of large-molecule drugs (including antibody drugs) entering clinical trials are ultimately approved for market, ...
- Source: drugdu
- 375
- September 2, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.